T2 Biosystms Stock Buy Hold or Sell Recommendation
| TTOO Stock | USD 0.22 0.01 4.35% |
Given the investment horizon of 90 days and your bold attitude towards risk, our recommendation regarding T2 Biosystms is 'Strong Sell'. The recommendation algorithm takes into account all of T2 Biosystms' available fundamental, technical, and predictive indicators you will find on this site.
Check out T2 Biosystms Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide. In addition, we conduct extensive research on individual companies such as TTOO and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards T2 Biosystms. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
TTOO |
Execute T2 Biosystms Buy or Sell Advice
The TTOO recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on T2 Biosystms. Macroaxis does not own or have any residual interests in T2 Biosystms or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute T2 Biosystms' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
T2 Biosystms Trading Alerts and Improvement Suggestions
| T2 Biosystms generated a negative expected return over the last 90 days | |
| T2 Biosystms has high historical volatility and very poor performance | |
| T2 Biosystms has some characteristics of a very speculative penny stock | |
| T2 Biosystms has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7.19 M. Net Loss for the year was (50.08 M) with loss before overhead, payroll, taxes, and interest of (24.77 M). | |
| T2 Biosystms currently holds about 13.21 M in cash with (48.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| T2 Biosystms has a frail financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 160 shares by Sperzel John J Iii of T2 Biosystms subject to Rule 16b-3 |
T2 Biosystms Returns Distribution Density
The distribution of T2 Biosystms' historical returns is an attempt to chart the uncertainty of T2 Biosystms' future price movements. The chart of the probability distribution of T2 Biosystms daily returns describes the distribution of returns around its average expected value. We use T2 Biosystms price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of T2 Biosystms returns is essential to provide solid investment advice for T2 Biosystms.
| Mean Return | -2.55 | Value At Risk | -14.29 | Potential Upside | 8.70 | Standard Deviation | 7.12 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of T2 Biosystms historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
TTOO Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as T2 Biosystms, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading T2 Biosystms back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Cwm, Llc Duplicate | 2024-09-30 | 310 | Group One Trading, Lp | 2024-09-30 | 289 | Advisor Group Holdings, Inc. | 2024-09-30 | 205 | Barclays Plc | 2024-09-30 | 101 | International Assets Investment Management, Llc | 2024-09-30 | 65.0 | Bank Of America Corp | 2024-09-30 | 56.0 | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 14.0 | Jjj Advisors Inc | 2024-06-30 | 9.0 | U.s. Bancorp | 2024-09-30 | 3.0 | Armistice Capital, Llc | 2024-09-30 | 1.4 M | Vanguard Group Inc | 2024-09-30 | 390.4 K |
T2 Biosystms Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 6.1M | 6.5M | (11.9M) | 4.4M | 3.9M | 4.1M | |
| Free Cash Flow | (44.0M) | (39.3M) | (51.0M) | (48.3M) | (43.5M) | (45.7M) | |
| Depreciation | 3.2M | 2.5M | 2.3M | 859K | 987.9K | 938.5K | |
| Other Non Cash Items | 3.3M | 3.9M | 3.1M | 773K | 889.0K | 1.7M | |
| Capital Expenditures | 804K | 460K | 339K | 192K | 172.8K | 164.2K | |
| Net Income | (46.8M) | (49.2M) | (62.0M) | (50.1M) | (45.1M) | (47.3M) | |
| End Period Cash Flow | 17.3M | 23.8M | 11.9M | 16.2M | 14.6M | 28.9M | |
| Change To Inventory | 441K | (1.9M) | (949K) | (744K) | (669.6K) | (703.1K) | |
| Change To Netincome | 12.5M | 8.1M | 7.0M | 10M | 11.5M | 8.1M | |
| Investments | (35.5M) | 25.3M | 9.7M | (202K) | (232.3K) | (243.9K) |
T2 Biosystms Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to T2 Biosystms or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that T2 Biosystms' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a TTOO stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -2.58 | |
β | Beta against Dow Jones | 0.24 | |
σ | Overall volatility | 7.18 | |
Ir | Information ratio | -0.37 |
T2 Biosystms Volatility Alert
T2 Biosystms is displaying above-average volatility over the selected time horizon. T2 Biosystms is a potential penny stock. Although T2 Biosystms may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in T2 Biosystms. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on TTOO instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.T2 Biosystms Fundamentals Vs Peers
Comparing T2 Biosystms' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze T2 Biosystms' direct or indirect competition across all of the common fundamentals between T2 Biosystms and the related equities. This way, we can detect undervalued stocks with similar characteristics as T2 Biosystms or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of T2 Biosystms' fundamental indicators could also be used in its relative valuation, which is a method of valuing T2 Biosystms by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare T2 Biosystms to competition |
| Fundamentals | T2 Biosystms | Peer Average |
| Return On Equity | -6.22 | -0.31 |
| Return On Asset | -0.9 | -0.14 |
| Operating Margin | (4.91) % | (5.51) % |
| Current Valuation | 23.03 M | 16.62 B |
| Shares Outstanding | 21.04 M | 571.82 M |
| Shares Owned By Insiders | 10.17 % | 10.09 % |
| Shares Owned By Institutions | 73.51 % | 39.21 % |
| Number Of Shares Shorted | 826.91 K | 4.71 M |
| Price To Earning | (2.04) X | 28.72 X |
| Price To Book | 14.50 X | 9.51 X |
| Price To Sales | 0.86 X | 11.42 X |
| Revenue | 7.19 M | 9.43 B |
| Gross Profit | (24.77 M) | 27.38 B |
| EBITDA | (43.88 M) | 3.9 B |
| Net Income | (50.08 M) | 570.98 M |
| Cash And Equivalents | 13.21 M | 2.7 B |
| Cash Per Share | 1.87 X | 5.01 X |
| Total Debt | 49.5 M | 5.32 B |
| Debt To Equity | 6.64 % | 48.70 % |
| Current Ratio | 1.87 X | 2.16 X |
| Book Value Per Share | (6.91) X | 1.93 K |
| Cash Flow From Operations | (48.14 M) | 971.22 M |
| Short Ratio | 1.26 X | 4.00 X |
| Earnings Per Share | (0.03) X | 3.12 X |
| Target Price | 5.0 | |
| Number Of Employees | 113 | 18.84 K |
| Beta | 0.38 | -0.15 |
| Market Capitalization | 10.48 M | 19.03 B |
| Total Asset | 34.8 M | 29.47 B |
| Retained Earnings | (584.3 M) | 9.33 B |
| Working Capital | (30.96 M) | 1.48 B |
| Current Asset | 77.78 M | 9.34 B |
| Current Liabilities | 18.54 M | 7.9 B |
Note: Disposition of 160 shares by Sperzel John J Iii of T2 Biosystms subject to Rule 16b-3 [view details]
T2 Biosystms Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as TTOO . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 64898.83 | |||
| Daily Balance Of Power | (0.50) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 0.23 | |||
| Day Typical Price | 0.23 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.01) |
About T2 Biosystms Buy or Sell Advice
When is the right time to buy or sell T2 Biosystms? Buying financial instruments such as TTOO Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having T2 Biosystms in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Warren Buffett Holdings Thematic Idea Now
Warren Buffett Holdings
A long-term portfolio of publicly-traded stocks on US exchanges that are owned by Warren Buffett's holding company Berkshire Hathaway. The Warren Buffett Holdings theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Warren Buffett Holdings Theme or any other thematic opportunities.
| View All Next | Launch |
Check out T2 Biosystms Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.03) | Revenue Per Share | Quarterly Revenue Growth (0.01) | Return On Assets | Return On Equity |
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.